JP2002506044A5 - - Google Patents

Download PDF

Info

Publication number
JP2002506044A5
JP2002506044A5 JP2000535362A JP2000535362A JP2002506044A5 JP 2002506044 A5 JP2002506044 A5 JP 2002506044A5 JP 2000535362 A JP2000535362 A JP 2000535362A JP 2000535362 A JP2000535362 A JP 2000535362A JP 2002506044 A5 JP2002506044 A5 JP 2002506044A5
Authority
JP
Japan
Prior art keywords
follistatin
functional fragment
disease
composition according
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000535362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506044A (ja
Filing date
Publication date
Priority claimed from US09/037,118 external-priority patent/US6004937A/en
Application filed filed Critical
Publication of JP2002506044A publication Critical patent/JP2002506044A/ja
Publication of JP2002506044A5 publication Critical patent/JP2002506044A5/ja
Withdrawn legal-status Critical Current

Links

JP2000535362A 1998-03-09 1999-02-24 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 Withdrawn JP2002506044A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/037,118 US6004937A (en) 1998-03-09 1998-03-09 Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US09/037,118 1998-03-09
PCT/US1999/004003 WO1999045949A2 (en) 1998-03-09 1999-02-24 Use of follistatin to modulate gdf-8 and bmp-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009222855A Division JP2010043099A (ja) 1998-03-09 2009-09-28 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2010061242A Division JP2010195794A (ja) 1998-03-09 2010-03-17 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用

Publications (2)

Publication Number Publication Date
JP2002506044A JP2002506044A (ja) 2002-02-26
JP2002506044A5 true JP2002506044A5 (https=) 2006-07-06

Family

ID=21892528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000535362A Withdrawn JP2002506044A (ja) 1998-03-09 1999-02-24 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2009222855A Pending JP2010043099A (ja) 1998-03-09 2009-09-28 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2010061242A Pending JP2010195794A (ja) 1998-03-09 2010-03-17 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009222855A Pending JP2010043099A (ja) 1998-03-09 2009-09-28 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2010061242A Pending JP2010195794A (ja) 1998-03-09 2010-03-17 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用

Country Status (11)

Country Link
US (1) US6004937A (https=)
EP (3) EP1061940B1 (https=)
JP (3) JP2002506044A (https=)
AT (1) ATE256475T1 (https=)
AU (1) AU759838B2 (https=)
CA (1) CA2322716C (https=)
DE (1) DE69913665T2 (https=)
DK (1) DK1061940T3 (https=)
ES (1) ES2212533T3 (https=)
PT (1) PT1061940E (https=)
WO (1) WO1999045949A2 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
BR9406715A (pt) * 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2001009368A1 (en) * 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
EP1790726B1 (en) * 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
KR100420798B1 (ko) * 2001-02-10 2004-03-02 (주)알에이싸이언스 펩타이드 벡터
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20030103959A1 (en) * 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6798160B2 (en) * 2001-11-02 2004-09-28 Honda Giken Kogyo Kabushiki Kaisha Electric working machine
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
CA2476887A1 (en) 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
EP2192129A1 (en) * 2002-09-16 2010-06-02 Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20050192225A1 (en) * 2002-12-18 2005-09-01 Bowen Richard L. Methods for treating Parkinson's disease
BRPI0410927A (pt) * 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
AU2004272072B2 (en) 2003-09-12 2010-07-08 Etex Corporation Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
CA2551877A1 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
JP2008526201A (ja) 2004-12-30 2008-07-24 シェーリング−プラウ・リミテッド 中和エピトープベースの成長増強ワクチン
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006232914A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to GDF-8 modulating agents
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
WO2008109779A2 (en) * 2007-03-07 2008-09-12 The Johns Hopkins University Use of follistatin-like related gene (flrg) to increase muscle mass
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ES3047691T3 (en) 2012-08-01 2025-12-04 Ikaika Therapeutics Inc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
US10023621B2 (en) 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
AU2016238254B2 (en) 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CA3124415A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041538A (en) * 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
DK0690873T3 (da) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
BR9406715A (pt) * 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
DE69434934D1 (de) * 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]

Similar Documents

Publication Publication Date Title
JP2002506044A5 (https=)
Carlstedt et al. Functional recovery in primates with brachial plexus injury after spinal cord implantation of avulsed ventral roots.
Barbeau et al. Enhancement of locomotor recovery following spinal cord injury
Spaić et al. Microsurgical DREZotomy for pain of spinal cord and Cauda equina injury origin: clinical characteristics of pain and implications for surgery in a series of 26 patients
EP3746126B1 (en) Methods and compositions for treating sleep apnea or simple snoring
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
Dietz et al. Recovery from spinal cord injury—underlying mechanisms and efficacy of rehabilitation
JP2002502413A (ja) 創傷治療のための部材及び方法
Sood et al. Treatment of painful neuromas of the hand and wrist by relocation into the pronator quadratus muscle
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
Nishimoto et al. Transcutaneous carbon dioxide application with hydrogel prevents muscle atrophy in a rat sciatic nerve crush model
Butler et al. Bupivacaine and Kaltostat reduces post-operative donor site pain
Sériès et al. Corticomotor control of the genioglossus in awake OSAS patients: a transcranial magnetic stimulation study
Carlstedt Approaches permitting and enhancing motoneuron regeneration after spinal cord, ventral root, plexus and peripheral nerve injuries
Pion et al. Transcutaneous and direct electrical stimulation of mouse sciatic nerve accelerates functional recovery after nerve transection and immediate repair
Vazquez et al. The effects of sensory stimulation on REM sleep duration
RU2120289C1 (ru) Способ лечения больных с неврологическими проявлениями остеохондроза позвоночника
de la Plaza et al. Can some facial rejuvenation techniques cause latrogenia?
SE1550338A1 (en) A composition for use in the treatment of intervertebral misalignment
Hayakawa et al. Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol–in vitro explant study
Sulaiman et al. Congenital fibre type disproportion with unusual clinico-pathologic manifestations.
AU6418296A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
Bruetsch et al. THE PARKINSONIAN SYNDROME DUE TO TRAUMA*: A Clinico-Anatomical Study of A Case
Jawa et al. Pathogenesis and classification of elbow stiffness
Ray et al. Effect of Moringa oleifera root extract on penicillin-induced epileptic rats